KIR gene variability in cutaneous malignant melanoma: Influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis

Immunogenetics

Volumn 65, Issue 5, 2013, Pages 333-343

  Campillo, José A ^a   Legaz, Isabel ^a   López Álvarez, M Rocío ^a   Bolarín, José Miguel ^a   Las Heras, Beatriz ^a   Muro, Manuel ^a   Minguela, Alfredo ^a   Moya Quiles, María R ^a   Blanco García, Rosa ^a   Martínez Banaclocha, Helios ^a   García Alonso, Ana M ^a   Álvarez López, M Rocío ^a   Martínez Escribano, Jorge A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

HLA class I ligands; KIR receptors; Melanoma; Sentinel lymph node metastasis; Ulceration

Indexed keywords

HLA ANTIGEN CLASS 1; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KIR2DL3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIR GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE METASTASIS; SKIN ULCER; GENETIC PREDISPOSITION; GENETICS; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; PATHOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN TUMOR;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HLA-C ANTIGENS; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; RECEPTORS, KIR2DL3; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84879006452     PISSN: 00937711     EISSN: 14321211     Source Type: Journal    
DOI: 10.1007/s00251-013-0682-0     Document Type: Article

References (50)

1. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, Field JK, Christmas SE (2010) Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Human Immunol 71:976-981
2. Anichini A, Vegetti C, Mortarini R (2004) The paradox of T cell mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855-864
3. Aranda-Romo S, García-Sepulveda CA, Comas-García A, Lovato-Salas F, Salgado-Bustamante M, Gómez-Gómez A, Noyola DE (2012) Killer-cell immunoglobulin-like receptors (KIR) in severe A (H1N1) 2009 influenza infections. Immunogenetics 64:653-662
4. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδ T cells, and antigen-specific CTL. J Immunol 160:5239-5245
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206
6. Bashirova AA, Martin MP, McVicar DW, Carrington M (2006) The killer immunoglobulin like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 7:277-300
7. Campillo JA, Martínez-Escribano JA, Muro M, Moya-Quiles R, Marín LA, Montes-Ares O, Guerra N, Sánchez-Pedreño P, Frías JF, Lozano JA, García-Alonso AM, Álvarez-López MR (2006a) HLA class I and class II frequencies in patients with cutaneous malignant melanoma from south-eastern Spain: the role of HLA-C in disease prognosis. Immunogenetics 57:926-933
8. Campillo JA, Martínez-Escribano JA, Moya-Quiles MR, Marín LA, Muro M, Guerra N, Parrado A, Campos M, Frías JF, Minguela A, García-Alonso AM, Álvarez-López MR (2006b) Natural killer receptors on CD8 T cells and Naural Killer cells from different HLA-C phenotypes in melanoma patients. Clin Cancer Res 12:4822-4831
9. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L, Ferlazzo G (2009) Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 4:e8132
10. Casado JG, Soto R, De la Rosa O, Peralbo E, del Carmen M-VM, Rioja L, Peña J, Solana R, Tarazona R (2005) CD8 T-cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother 54:1162-1171
11. Casado JG, Pawelec G, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R (2009) Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother 58:1517-1526
12. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B (2007) KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 179:854-868
13. Chouaib S, Thiery J, Gati A, Gerra N, El Behi M, Dorothée G, Mami-Chouaib F, Bellet B, Caignard A (2002) Tumor escape from killing: Role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 60:273-281
14. Cochran AJ, Huang R-R, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659-670
15. Cognet C, Farnarier C, Gauthier, Frassati C, André P, Magérus-Chatinet A, Anfossi N, Rieux-Laucat F, Vivier E, Schleinitz N (2010) Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin Immunol 135:26-32
16. Du Z, Gjertson DW, Reed EF, Rajalingam R (2007) Receptor-ligand analyses define minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics 59:1-15
17. Fauriat C, Ivarsson MA, Ljunggren H-G, Malmberg K-J, Michaëlsson J (2010) Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115:1166-1174
18. Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, Witt CS (2008) The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood 112:435-443
19. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89-95
20. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, Gleimer M, Hammond JA, Guethlein LA, Bushnell DA, Robinson PJ, Parham P (2009) KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A11 while diminishing avidity for HLA-C. J Exp Med 206:2557-2572
21. Hansasuta P, Dong T, Thananchai H, Weekes M, Willber C, Aldemir H, Rowland-Jones S, Braud VM (2004) Recognition of HLA-A3 and HLA-11 by KIR3DL2 is peptide-specific. Eur J Immunol 34:1673-1679
22. Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA (2012) Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations. Immunogenetics 64:719-737
23. Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, Gruda R, Achdout H, Drize O, Merims S, Mandelboim O (2004) MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 173:1819-1825
24. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp ME, Khakoo SI (2010) Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51:1168-1175
25. Konjevic G, Mirjacic Martinovic K, Jurisic V, Babovic N, Spuzic I (2009) Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biormarkers 14:258-270
26. Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF (2008) A HLA-Cw0701 restricted melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother 57:745-752
27. Lee PP, Yee C, Savage PA, Fong L, Brokstedt D, Weber J, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685
28. Maat W, Van der Slik AR, Verhoeven DH, Alizadeh DZ, Ly LV, Verduijn W, Luyten GP, Mulder A, van Hall T, Koning F, Jager MJ, van Bergen J (2009) Evidence for Natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Investig Ophthalmol Vis Sci 50:2888-2895
29. Mandelboim O, Reyburn HT, Valés-Gómez M, Pazmany L, Colonna M, Borsellino G, Strominger JL (1996) Protection from lysis by Natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 184:913-922
30. Martayan A, Fraioli R, Giorda E, Setini A, Ciccarelli G, Delfino L, Ferrara GB, Giacomini P (1999) Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer 80:639-649
31. Martin MP, Borecki IB, Zhang Z, Nguyen L, Ma D, Gao X, Qi Y, Carrington M, Rader JS (2010) HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics 62:761-765
32. Middleton D, Gonzelez F (2010) The extensive polymorphism of KIR genes. Immunology 129:8-19
33. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P (2008) Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 180:3969-3979
34. Moreta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223
35. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18:151-158
36. Nasca R, Carbone E (1999) Natural killer cells as potential tools in melanoma metastatic spread control. Oncol Res 11:339-343
37. Naumova E, Mihaylova A, Milena I, Mihailova S (2007) Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. Cancer Immunol Immunother 56:95-100
38. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M (2005) Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 54:172-178
39. Parham P (2004) NK cells lose their inhibition. Science 305:786-787
40. Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201-214
41. Pende D, Accame L, Pareti L, Mazzocchi A, Moretta A, Parmiani G, Moretta L (1998) The susceptibility to natural killer cell-mediated lysis of HLA class-I positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384-2394
42. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A (2009) Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113:3119-3129
43. + T lymphocytes. J Immunol 180:2767-2771
44. Tajik N, Shahsavar F, Poormoghim H, Radjabzadeh MF, Mousavi T, Jalali A (2011) KIR3DL1 + HLA-B Bw4Ile80 and KIR2DS1 + HLA-C2 combinations are both associated with ankylosing spondylitis in the Iranian population. Int J Immunogenet 38:403-409
45. Thielens A, Vivier E, Romagné F (2012) NK cells MHC class I specific receptors (KIR) from biology to clinical intervention. Curr Opin Immunol 24:239-245
46. Tiwari JL, Terasaki PI (1985) The data and statistical analysis. In: Tiwary JL, Terasaki PI (eds) HLA and disease associations. Springer, New York, p 18
47. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC (2012) HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 367:805-816
48. Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C (2009) Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 58:855-865
49. Vilches C, Castaño J, Gómez-Lozano N, Estefania E (2007) Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. Tissue Antigens 70:415-422
50. Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, Pavlick AC, Kopf AW, Polsky D, Osman I (2008) Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 113:3341-3348